

F. No. CT/10/2011-DCGI (I)
Directorate General of Health Services
Office of Drugs Controller General (India)
(Biological Division)

FDA Bhawan New Delhi

Dated: **8 JUL 2011**

To,

M/s. Novo Nordisk India Pvt. Ltd.
Plot No. 32, 47-50
EPIP Area, Whitefield,
Bangalore-560 066

Subject: "A trial completing the efficacy and safety of Insulin degludec/liraglutide, Insulin Degludec and liraglutide in subjects with Type 2 diabetes-A 26 week randomized, parallel three arm, open label, multicenter, multinational treat to target trial comparing fixed ratio combination of Insulin Degludec and liraglutide versus insulin degludec or liraglutide alone, in subjects with Type 2 diabetes treated with 1-2 oral antidiabetic drugs (OADs), Protocol No. NN9068-3697 -regarding

Reference: Your letter No. NN/MED/RA/MZUH/2011/178, dated 23 may, 2011 (Dy. No. 25164, dated 25.05.2011)

Sir,

This Directorate has no objection to your conducting clinical trials with the said drug under the supervision of the investigators mentioned in your letter and as per the protocol forwarded to this Directorate. At the time of submitting clinical trials reports to this Directorate for evaluation you are required to comply with the following requirements:-

1. Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug.
2. Indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multi-centric).
3. Approval of the Ethical Committee of the concerned centre/institution for conducting the clinical trial with the said drug.


You are requested to submit to this Directorate an annual status report on each clinical trial viz. ongoing, completed or terminated. In case the trial is terminated the reasons for the same should be communicated to this Directorate. In case any unexpected serious adverse reaction is observed during trial, the same should be immediately communicated.

It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

You are also requested to follow Ethical aspects of the clinical trial as described in the booklet "Ethical Guidelines for Biomedical Research on Human Subjects" published by Indian Council of Medical Research (ICMR), New Delhi, and 'GCP' guideline issued by this Department and to obtain Ethical Committee clearance of the Institute before initiation of the study. Ethical Committee clearance should be obtained before initiation of the study.

- It is mandatory to register this clinical trial at ICMR clinical trial registry at www.ctri.in before enrolling first patient in the study.
In future correspondence, you may intimate this Directorate that you have registered the study as mentioned above and also mention the registration number in all your correspondences.
- In case of study related injury or death, you will provide complete medical care as well as compensation for the injury or death and statement to this effect should be incorporated in the Informed Consent Form. Further in case of such injuries or deaths the details of compensation provided should be intimated to this Directorate.

Yours faithfully,



(Dr. Surinder Singh)
Drugs Controller General (India)